JP2023550832A5 - - Google Patents

Info

Publication number
JP2023550832A5
JP2023550832A5 JP2023532306A JP2023532306A JP2023550832A5 JP 2023550832 A5 JP2023550832 A5 JP 2023550832A5 JP 2023532306 A JP2023532306 A JP 2023532306A JP 2023532306 A JP2023532306 A JP 2023532306A JP 2023550832 A5 JP2023550832 A5 JP 2023550832A5
Authority
JP
Japan
Prior art keywords
sequence
variable region
chain variable
seq
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/133083 external-priority patent/WO2022111576A1/en
Publication of JP2023550832A publication Critical patent/JP2023550832A/ja
Publication of JP2023550832A5 publication Critical patent/JP2023550832A5/ja
Pending legal-status Critical Current

Links

JP2023532306A 2020-11-27 2021-11-25 CD39およびTGFβを標的とする新規のコンジュゲート分子 Pending JP2023550832A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020132392 2020-11-27
CNPCT/CN2020/132392 2020-11-27
CN202111396829 2021-11-23
CN202111396829.4 2021-11-23
PCT/CN2021/133083 WO2022111576A1 (en) 2020-11-27 2021-11-25 Novel conjugate molecules targeting cd39 and tgfβeta

Publications (2)

Publication Number Publication Date
JP2023550832A JP2023550832A (ja) 2023-12-05
JP2023550832A5 true JP2023550832A5 (cg-RX-API-DMAC7.html) 2024-11-21

Family

ID=81755308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532306A Pending JP2023550832A (ja) 2020-11-27 2021-11-25 CD39およびTGFβを標的とする新規のコンジュゲート分子

Country Status (9)

Country Link
US (1) US20230416394A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251650A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550832A (cg-RX-API-DMAC7.html)
KR (1) KR20230113752A (cg-RX-API-DMAC7.html)
CN (1) CN115052894A (cg-RX-API-DMAC7.html)
AU (1) AU2021389989A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202988A1 (cg-RX-API-DMAC7.html)
TW (1) TW202237651A (cg-RX-API-DMAC7.html)
WO (1) WO2022111576A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
TW202340243A (zh) 2022-03-03 2023-10-16 美商阿克思生物科學有限公司 抗cd39抗體及其用途
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024175760A1 (en) 2023-02-24 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
SG11202000820PA (en) * 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CN119431579A (zh) * 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法
CN113754768B (zh) * 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
CN112672753B (zh) * 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
WO2021007428A2 (en) * 2019-07-09 2021-01-14 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체

Similar Documents

Publication Publication Date Title
AU2020415159B2 (en) Anti-LILRB1 antibody and uses thereof
CN117946274B (zh) 抗cd73抗体及其应用
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2024544520A5 (cg-RX-API-DMAC7.html)
JP2021524278A (ja) 抗メソテリン抗体
JP2020501531A5 (cg-RX-API-DMAC7.html)
WO2019222428A1 (en) Composition of bispecific antibodies and method of use thereof
CN115551889A (zh) 抗cd73抗体及其用途
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2022507679A (ja) Her2/pd1二重特異性抗体
CN110831973A (zh) 多特异性抗体及其制备和使用方法
CN110799540A (zh) 多特异性抗体及其制备和使用方法
JP2022534297A (ja) 抗b7-h3抗体
JP7392145B2 (ja) 免疫療法のためのt細胞二重特異性抗体の作製における最適化された抗cd3アーム
TW202221035A (zh) 抗ilt2抗體及其用途
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
EP4299594A1 (en) Gucy2c binding polypeptide and uses thereof
CN113943371A (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
JP2023525991A5 (cg-RX-API-DMAC7.html)
CN120731229A (zh) FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分
CN110662764B (zh) 抗程序性死亡配体1(pd-l1)抗体及其治疗用途
JP2024527043A5 (cg-RX-API-DMAC7.html)
CN117677635A (zh) 新颖pd-1结合域
Wang et al. The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
WO2026046336A1 (zh) Trop2/MUC1结合分子及医药用途